Trichostatin A (TSA)

目录号:S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2653.01 现货
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系,包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖,平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系,抑制HDAC活性,平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同,Trichostatin A 抑制这些HDACs,且抑制程度相似, IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞,通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体,而诱导转化生长因子βⅡ型受体(TβRII) 表达,复合体与TβRII 启动子的DNA片段结合,伴随着Sp1乙酰化,且与复合体相关的HDAC数理全部降低。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MUnGeY5kfGmxbjDBd5NigQ>? NVLlNI1MOC55zszN M33x[|I1cA>? M3nGN4V1cGGwb3y= NXyzOnc6\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= MnHPNlU4QDdyN{m=
TE13 NYexWFZ{TnWwY4Tpc44hSXO|YYm= MUCwMlPPxE1? MYeyOIg> NGTxUGR2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MkPwNlU2Pzl4NkW=
TE13 M4HGbmFxd3C2b4Ppd{BCe3OjeR?= M3;SclAvO87:TR?= MkTKNlRp MVvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MljHNlU2Pzl4NkW=
MEFs MlPpSpVv[3Srb36gRZN{[Xl? NYHpPWlUPc7:TR?= M2\SdlE3cA>? NILrVo5qdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MWOyOVQ5OjZ|NB?=
SW480  NWr4cmFzTnWwY4Tpc44hSXO|YYm= NH63O4YxNjIQvF2= M4T3b|Q5cA>? NXTjWYdDTE2VTx?= NGXBZlFz\X[ncoPld{BGVVR? NFm3VYEzPTR|NEm5Oy=>
PC3  M33oO2Z2dmO2aX;uJGF{e2G7 M1PUTlAvOc7:TR?= NHSzW4k1QGh? NUPJblZHTE2VTx?= MnLFdoV3\XK|ZYOgSW1V MmDxNlU1OzR7OUe=
SW480  NELpdXlHfW6ldHnvckBCe3OjeR?= M{PvXlAvOc7:TR?= M4f2[lQ5cA>? M3faUGROW09? NUDHd3M4[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NY\FfGNIOjV2M{S5PVc>
PC3  MUDGeY5kfGmxbjDBd5NigQ>? M1zN[VAvOc7:TR?= MmLVOFhp MYjEUXNQ NY\2WW5P[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MnXtNlU1OzR7OUe=
SW480  MnuySpVv[3Srb36gRZN{[Xl? M2XpPVAvOc7:TR?= NH[zdm01QGh? NIHmVm9FVVOR NXHrRW5JcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= Mn7KNlU1OzR7OUe=
PC3  NUP3U2p7TnWwY4Tpc44hSXO|YYm= NVrlV4JmOC5zzszN M{LiO|Q5cA>? MkjySG1UVw>? MUPpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz NXjINXUzOjV2M{S5PVc>
A431 MUXBdI9xfG:|aYOgRZN{[Xl? NUTHfFRDOi9zMD:1NE8yODCwTR?= NVzvc2hrPDiq MmXKSG1UVw>? NIPucoNqdmirYnn0d{B1cGViY3XscEBoem:5dHi= MUKyOVM4OTB4OR?=
A431 MV3GeY5kfGmxbjDBd5NigQ>? MUm1NI5O MYSyM|YwOTJxMkTo Mn\DSG1UVw>? MYrhZ5RqfmG2ZYOgdFIyKGGwZDDpcohq[mm2czDBWGY{KGW6cILld5Nqd25? MmDDNlU{PzFyNkm=
MDA-MB-231 NHXufoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5NE03ODCwTR?= MojQNlRp M2TjVmROW09? NWDpU5h6UUN3MDDv[kAyODCwTR?= M2HEXFI2OTl{N{Kx
MCF7 NXn2PIhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrzRo8xNTZyMH7N M1;TZlI1cA>? NF;wV4tFVVOR NXTK[YRpUUN3MDDv[kA4PW6P NX63UWp7OjVzOUK3NlE>
SKOV-3 M3rnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xMVEx|ryP NHnUfVUzPGh? MnzMSG1UVw>? M{HUbGlEPTBib3[gOU43|ryP NEXCUoEzPTF4OUS5NS=>
A549 M3L1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwdWwyNTFyzszN M{nwRVI1cA>? MnjuSG1UVw>? NYf4V3l{UUN3MDDv[kA{NjMQvF2= M4PSbVI2OTZ7NEmx
SKOV-3 NI\HSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj0d291OC5zLUJOwG0> MUe0PIg> NFfLUHZFVVOR MkS0TWM2OCCxZjCwMlfPxE1? NYjnc3BSOjVzNkm0PVE>
A549 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMlEuOc7:TR?= MoLVOFhp NWj5e29lTE2VTx?= M3vRRWlEPTBib3[gNE4zQM7:TR?= NVHUUlB3OjVzNkm0PVE>
SKOV-3 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHR[5Z2OC5yMT2wMlnPxE1? MUO3Nog> MnflSG1UVw>? M3SwfWlEPTBib3[gNE4{Os7:TR?= NIT5emEzPTF4OUS5NS=>
A549 NY\FNFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnENE4xOS1yLkpOwG0> M4nJdVczcA>? NVjHV|J6TE2VTx?= Mlu5TWM2OCCxZjCwMlA3|ryP NEj6PJUzPTF4OUS5NS=>
HeLa NG[5c4JHfW6ldHnvckBCe3OjeR?= MnrENlUxdk1? NX;QTVgxOT[q Mni2SG1UVw>? NF3QRlRqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg NUCwemR{OjVzMU[2PFg>
CNE2 M4n6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvL[ldmOTByLU[wNI5O NHO5RYszPC92OD:3Nog> MU\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnXHNlQ6Pjl7MEG=
PC3 NHPvNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofrNVAxNTFyMEDuUS=> MV2yOIg> M1vNTGlEPTBib3[gN|Axdk1? NVL5fmV6OjR6NUS2OVg>
LNCaP M1\vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNFAuOTByMH7N MlLqNlRp NVLVNFRVUUN3MDDv[kA{ODCwTR?= MV[yOFg2PDZ3OB?=
HeLa  NYrFV|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO2SJoz|ryP MkjqOFhp MXLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn MX6yOFg1PjF|NR?=
HMEC-1  MYPGeY5kfGmxbjDBd5NigQ>? MnjKN|Axdk1? MVOyOIg> MWPpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MUeyOFcyODZ|MR?=
HeLa M{S1SGZ2dmO2aX;uJGF{e2G7 NGjIWGUydU1? NFnwblIxNjWq M1HtdoFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= MljpNlQ4ODd2N{S=
ACP02 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfiSGszPTBxM{WwM|UxOG6P NUfzfmJ1OjSq NVzNb41C\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= NXjZRoVZOjR4Nki1OFc>
ACP03 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjS[5AzPTBxM{WwM|UxOG6P MWqyOIg> MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O MYCyOFY3QDV2Nx?=
U87 GBM Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TUcVExOC9|MECvOVAxKG6P M3PCSVczKGh? NUn6W|FNOTByJTDleIhidm:u NEfRV4Jz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> MoTjNlQ1PjR6NEG=
U87 GBM NVvJOnRWTnWwY4Tpc44hSXO|YYm= NWnX[5o5OTByL{WwNEBPdQ>? MYS0PEBp M2TGZlExOCViZYToZY5wdA>? MXLJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> M1nCV|I1PDZ2OESx
RPE MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy5[20xNjJxMD60M|AvQC9zIN88US=> MVuyOE81QC95MjDo NHqwUYFFVVOR NFPtVHhqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? NX7FVZBnOjR2NU[2NFI>
HT29  M2\DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiyXlYyQDBibl2= NVr5NmJ2PzJiaB?= NEmweXhKSzVyIH;mJFE5OCCwTR?= MX2yOFM3QDJ4NR?=
hMSCs NVO3VHR5TnWwY4Tpc44hSXO|YYm= M4\ZdVYvOjVibl2= NHz3W4QzPCCq NYXReJFPTE2VTx?= Ml7Fd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= Mmf0NlQ{OTJ|NU[=
Huh7  M3LmO2Z2dmO2aX;uJGF{e2G7 NVTJUpdVOC5zL{CuOU8yNjBizszN MlHSNlRp MVTzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? MX[yOFI3QTZ5Mh?=
SKOV3 NUnjVFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMlA2NTJizszN MXyxNE8zPC92ODDo NXjTfmNCTE2VTx?= NX\5UopqdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2fLUVI1OjJ|OECx
A2780 M1LZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fKe|AvODVvMjFOwG0> MoC1NVAwOjRxNEigbC=> NX:wfJJxTE2VTx?= NFfPSYJu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M4fNWVI1OjJ|OECx
SRA01/04  NGHBOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jyW|AvOiEQvF2= M2H5PVQ5KGh? NFGyNo5FVVOR NUPBdXBye3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MkLINlQyPTd6N{i=
HLEB3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zHcVAvOiEQvF2= NFzTO4g1QCCq NFPqfnBFVVOR MoD0d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> MWiyOFE2Pzh5OB?=
SRA01/04  MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PNVAvPC9yLkig{txO MYK0PEBp MYrEUXNQ MoLZbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M2LqclI1OTV5OEe4
HLEB3 NWH2[ZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjOV2NNOC52L{CuPEDPxE1? M4jLR|Q5KGh? NGCxcVJFVVOR MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3LMW|I1OTV5OEe4
HCT116 M4[yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHMSId{OC5{IN88US=> NUTaS2RHOTJiaB?= NV7ONGNO\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> MkfWNlQyOjJ{M{G=
CA46 M4nRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HuPVMwPi9zMj:yOE81QCCwTR?= NILYdpI1QCCq M2S5SYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NFnLRm0zPDB4NEm1NS=>
PMNs MkjGSpVv[3Srb36gRZN{[Xl? NHvmWJc{OCCwTR?= NX7tRXpOPDhiaB?= NF\qeI9qdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> M2\1OVI{QTh6NkG3
H1299 NFHsOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxxsDPxE4EoB?= NWGydFE3OjRxNEivO|IhcA>? M{TJWIV1cGGwb3y= M2fpdYlv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? NHe0SoczOzlzNk[wPS=>
A549 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiwMlI2NzBwNT:xJO69VQ>? NWLGPGlOOjRxNEivO|IhcA>? MYXleIhidm:u M3q3eIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NWPYWlMzOjN6Nke5PVE>
H1299 M2izXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXZNE4zPS9yLkWvNUDPxE1? NXXSbJpZOjRxNEivO|IhcA>? M1q5boV1cGGwb3y= MlO0bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M{\mU|I{QDZ5OUmx
A549 NH3qfJNCeG:ydH;zbZMhSXO|YYm= Mkj1NE42NzFizszN M4DQTFQ5KGh? NGXqcWxmfGijbn;s NGPLO|dqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoDFNlM5Pjd7OUG=
H1299 MUnBdI9xfG:|aYOgRZN{[Xl? M2PSNlAvPS9zIN88US=> MnG2OFghcA>? MkPm[ZRp[W6xbB?= NWDmZZFNcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmnmNlM5Pjd7OUG=
SUM149PT M1\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3yzNVIwPy53L{GwJO69VQ>? MmnSOFghcA>? M1HvS2ROW09? MYXpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? NH7adlEzOzd7Mk[zPC=>
SUM190PT MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPQVYQ2OC9zMECvNlUxKG6P NF3DSo41QCCq NHrEZW5FVVOR NXLCN2NScW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 M3LBeVI{Pzl{NkO4
HCT1 NGL1UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMlIwOS5yL{WuNEDPxE1? MnrENVIwOjRxM{[vOFghcA>? NFnlb2pqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NVP4TpJDOjN5N{CwNFA>
Lovo MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe5Z2pXOC5{L{GuNE82NjBizszN NIPwVmMyOi9{ND:zOk81QCCq MXrpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MWeyN|c4ODByMB?=
AGS NHPFUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\6O2QxNjBzNT2xJO69VQ>? NWO3bZA{PzJiaB?= Mm\ybY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NVrGOmloOjN5NEWwNlQ>
Huh7 M2jzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnCNUDPxE1? NY[1ZnhkOjRiaB?= NXXh[o9nTE2VTx?= Mn31doVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NYP6dFBpOjN4NEO5N|M>
ECC1 MXvGeY5kfGmxbjDBd5NigQ>? MUi1NFAhdk1? Mn:yOUBl NWm2bnUxTE2VTx?= M374Xolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M3;MSVI{PTNyN{[5
HEC1A NGHlT4hHfW6ldHnvckBCe3OjeR?= M4K0WVUxOCCwTR?= M3X2WlUh\A>? M{fHO2ROW09? M1S5O4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MVKyN|U{ODd4OR?=
EN1 NID3TlBHfW6ldHnvckBCe3OjeR?= M2\DelUxOCCwTR?= MW[1JIQ> MlPRSG1UVw>? M2nlNolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NGPsV5YzOzV|MEe2PS=>
MFE296 NGL4Z5BHfW6ldHnvckBCe3OjeR?= MkPjOVAxKG6P NH;jNZc2KGR? MnPKSG1UVw>? M2Ticolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NITlenozOzV|MEe2PS=>
HASMCs NU\yW|BDTnWwY4Tpc44hSXO|YYm= MUWwMVUxOCCwTR?= MXm2JIQ> MnjJ[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> MYGyN|UyQDR4Nx?=
U373 NYDBVotTTnWwY4Tpc44hSXO|YYm= M1Kz[VAvOjVxMD61M|Eh|ryP NVz5dGVoOjRiaB?= NUfmRXJycW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= NVLhcVNJOjN2N{SxO|E>
ARN8  Ml36SpVv[3Srb36gRZN{[Xl? MmTWNE4xPS1{IN88US=> M1W3UFI1KGh? NXjZU|RLemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NG\qU48zOzR5MEW0NC=>
MCF7 MUDGeY5kfGmxbjDBd5NigQ>? MoroNE4xPS1{IN88US=> MVSyOEBp NVHQW2dYemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NVLkXoVlOjN2N{C1OFA>
H1299  MorvSpVv[3Srb36gRZN{[Xl? MnTDNE4{O+LCk{JCpOK2VQ>? MXGyOE81QCCq Mn3wSG1UVw>? M4izeYlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= M1z0TlI{PDZzOUe1
H1299 MkfSSpVv[3Srb36gRZN{[Xl? M324[FAvPSEQvF2= MlLROFghcA>? MUHEUXNQ MlTPbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> MWeyN|Q3OTl5NR?=
H1299 M2XNS2Z2dmO2aX;uJGF{e2G7 Mn3oNE42KM7:TR?= NYnxcFV[PDhiaB?= NHfTZXFFVVOR MYnpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MXWyN|Q3OTl5NR?=
MG-63  NI\rcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m4WVAvOyEQvF2= MYKxNk06PiCq M{Loc2ROW09? NXW4dnZRcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NYT0SmN6OjN2NUG4NVc>
LM8 NXrhO3BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzNWcxNjNizszN MUexNk06PiCq NYLueVgyTE2VTx?= NFThOFFqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MVuyN|Q2OThzNx?=
K562 NX3lRoFUTnWwY4Tpc44hSXO|YYm= MWqwMlUh|ryP M1u5ZlI1KGh? M1\IOYV1cGGwb3y= MXTk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M4XVW|I{PDNyOUW3
HEL MUnGeY5kfGmxbjDBd5NigQ>? MWmwMlUh|ryP M3S3flI1KGh? NWewW5BH\XSqYX7vcC=> MX\k[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NFi0TJAzOzR|MEm1Oy=>
HL60 MorERZBweHSxc3nzJGF{e2G7 MVWxJO69VQ>? NYnleVNIOjRiaB?= M4XPbYlv\HWlZYRCpINmdGxiZHXheIg> MlPYNlM1ODB3MUm=
KG1 NV;nSmw6SXCxcITvd4l{KEG|c3H5 NWrLcmFuOSEQvF2= Mly2NlQhcA>? Mm\5bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MkPTNlM1ODB3MUm=
Kazumi NEjRV4lCeG:ydH;zbZMhSXO|YYm= NWLaTGlTOSEQvF2= M3LSZlI1KGh? MVTpcoR2[2W|wrDj[YxtKGSnYYTo MonBNlM1ODB3MUm=
K562 MmX4RZBweHSxc3nzJGF{e2G7 M1zuc|Eh|ryP NXToVpo3OjRiaB?= Mn\xbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MYWyN|QxODVzOR?=
THP1 NHrtcG1CeG:ydH;zbZMhSXO|YYm= Mo\TNUDPxE1? NIrQ[3QzPCCq MlXxbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NYLLfFdKOjN2MEC1NVk>
SH-SY5Y M1zRS2Z2dmO2aX;uJGF{e2G7 MVWyOVAhdk1? NUXNfFlnOTZiaB?= NXzu[2dC[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> MnrrNlM{OjZ2MkK=
HEK293 MnLTSpVv[3Srb36gRZN{[Xl? NHLJdGgyKML3TdMg NEK2eGwyQCCqwrC= NFLHN5lqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| NI\mWYszOzJ6NEi0PC=>
HTK NVPH[mF7TnWwY4Tpc44hSXO|YYm= M2fzTVQxOCCwTR?= MknzO|IhcA>? M4S5bIlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> M2TPN|I{Ojh2MECy
HTK NYWwV2dxTnWwY4Tpc44hSXO|YYm= MlfHNVAxNThyMH7N MX63NkBp NVz2[Wp4[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= NWPFNVBIOjN{OESwNFI>
Caco-2  NF[0bVlHfW6ldHnvckBCe3OjeR?= M1mxUFEhyrWPwrC= M4eyOlI1KGh? NIjtSHJl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= NVn5UWtlOjNzOUWwO|A>
HeLa NWfhcHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XLNFExOCCwTR?= NGfIdJkzPCCq M2Dpd2ROW09? MYfJR|UxKG:oIEGwNI5O MUCyN|E3PTd2OB?=
HeLa MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HKS|QxKG6P Mor6OFghcA>? NIrOOZNFVVOR M3nuVmlEPTBib3[gOFBvVQ>? MnOxNlMyPjV5NEi=
HeLa NWji[4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiyNEBvVQ>? MXO3NkBp MnThSG1UVw>? NHLLXFNKSzVyIH;mJFIxdk1? M1PrSlI{OTZ3N{S4
HeLa NHnLU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSxZ3ZEOTBxM{CvOVAhdk1? NGfLZ|M4OiCq NX3GTXp4TE2VTx?= NUjQ[XVIcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 M2jNdlI{OTZ3N{S4
MDA-MB-231 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvqZm0zPS12MECgcm0> NVjjSmdKPDhiaB?= Mom2TWM2OCCxZjCyOlMvOm6PwrC= NWH0TYtCOjNyNUWxPVg>
MCF-7  NVHycY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXOb4EzPS12MECgcm0> M3v2OFQ5KGh? NXqxXYZ[UUN3MDDv[kAzOjBwNH7N NXjSXY5TOjNyNUWxPVg>
ECC-1  NEjPc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNFAhdk1? NWft[WMyOjRiaB?= MmTH[ZRp[W6xbB?= NYTQRmk1cW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl NXf5[mlEOjNyMki4NFM>
HEC-1A Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT5ZWVjOTByIH7N MXWyOEBp NWjMZWxQ\XSqYX7vcC=> M4fqOolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= MYWyN|AzQDhyMx?=
NHAC-kn M1jOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[2N4VHOTBxMUCwM|UxOCCwTR?= MlHSNVIhcA>? MULEUXNQ MlXCTWM2OCCxZjC1NFBvVQ>? NXvSWY1ZOjNyMUe4O|E>
A549 NVj0NGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfsPIMzPTBibl2= Mon4Ok04OiCq MWrEUXNQ NYO3SXdH[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NWXycYVbOjJ7OUS3PFA>
MG-63 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T0PVMxOCCwTR?= MXmxNkBp NH7pXo1FVVOR NIC2S21qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn MnHaNlI4QTl|M{i=
MG-63 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLDUWw{ODBibl2= NX\CbpdCOjRiaB?= MXrEUXNQ M3nlNIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? MXSyNlc6QTN|OB?=
MG-63 M4nlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvvemhuOzByIH7N M3TrSlQ5KGh? NUi0bWJzTE2VTx?= NFPSbW1qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn NWDLWHM4OjJ5OUmzN|g>
HL60  NX7qR2VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VNVUxNTN3MDDuUS=> MmDzNlQhcA>? NVj3OmdHcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NYT4cHd4OjJ5NUO3N|k>
U937 NUm5b2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jzZVE2OC1|NUCgcm0> MmLXNlQhcA>? M1qzVYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NHLrbmwzOjd3M{ezPS=>
SCC-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TJd|IxOC1|MkCwJI5O MVKxNk8zPC92ODDo MY\EUXNQ M1WzPIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NVLTbnRQOjJ3NUKzNlE>
U87  NYnDVIs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7jNVAxNTNyMDDu[y=> NWHrPWo5OjRiaB?= NF\MOY5qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MV:yNlI4ODh2OR?=
K562 NEPPRmNHfW6ldHnvckBCe3OjeR?= NGDHblcyKM7:TR?= Mmr6NVIhcA>? NI\Ce|dFVVOR NFjaZ2hmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NUXxWWdZOjJzN{mxPVg>
Reh MlO2SpVv[3Srb36gRZN{[Xl? NID0foQxNjNxMTFOwG0> MV6xNkBp MVrEUXNQ M1XaTIVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NUnJ[2tVOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型,持续处理4周,具有有效的抗癌活性,即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症(SMA)模型鼠,导致乙酰化的 H3 和 H4组蛋白水平提高,也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠,促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时,或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火,然后使用600 μL 乙酸乙酯进行抽提,通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据,绘制合适的剂量反应曲线,而测定IC50。
细胞实验:[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3

CAS号 58880-19-6
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Related Antibodies

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID